广州医药2025，Vol.56Issue(2)：151-159,9.DOI:10.20223/j.cnki.1000-8535.2025.02.002
MDSCs在肿瘤免疫治疗中的研究进展
Research progress of MDSCs in tumor immunotherapy
摘要
Abstract
Solid tumors exhibit a very limited response to immunotherapy.Consequently,effectively enhancing the therapeutic efficacy of tumor immunotherapy has emerged as a critical challenge and problem that urgently needs to be addressed in tumor immunotherapy.The chemotaxis and recruitment of myeloid-derived suppressor cells(MDSCs)and the tumor immune evasion mechanisms mediated by them are one of the core factors that significantly restrict the efficacy of immunotherapy for solid tumors.In this review,we discuss the origins and phenotypic characteristics of MDSCs,the specific mechanisms by which they mediate tumor immune evasion,as well as current targeted therapeutic strategies for MDSCs and the latest research progress in combining MDSC-targeted therapy with tumor immunotherapy.Furthermore,we have systematically analyzed the key challenges faced by the combination of MDSC-targeted and immunotherapy strategies,and accordingly proposed a precise targeting strategy for MDSCs.This strategy aims to precisely activate anti-tumor immune responses,providing more personalized and efficient treatment options for cancer patients,thereby opening a new era in tumor immunotherapy and contributing to the innovation and development of cancer treatment strategies.关键词
肿瘤免疫治疗/免疫逃逸/髓系来源抑制性细胞/联合治疗Key words
tumor immunotherapy/immune evasion/myeloid-derived suppressor cells(MDSCs)/combination therapy引用本文复制引用
姚远,尹亭亭..MDSCs在肿瘤免疫治疗中的研究进展[J].广州医药,2025,56(2):151-159,9.基金项目
国家自然科学基金青年项目(82003125) （82003125）
广州市基础与应用基础研究专题(青年博士"启航"项目)(2024A04J4009) （青年博士"启航"项目）
广州市基础与应用基础研究项目(博士青年科技人员类)(202102021249) （博士青年科技人员类）
广州市校(院)联合资助(登峰医院)基础研究项目(202201020269) （院）
